Best Oncology Companies in Spain
The 79 best Oncology companies in Spain in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: UDX.
- Oncology R&D: emerging therapies and new challenges
- Oncology Market Size to Surpass USD 903.81 Billion by 2034
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Spain
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UDX Developer of non-invasive blood-based diagnostics for cancer | $126M | 5 mo ago | Series C | 61 | Marko Bitenc Co-Founder | WebflowApple iCloud MailMicrosoft 365+11 | — | — |
| 2 | Cinfa Biotech Spanish clinical-stage biosimilar development company | $93M | 156 mo ago | Acqui-Hired | 2 | — | — | 8 patents Syringe calibration devices for precise drug dosing and G‑CSF efficacy testing | — |
| 3 | MedLumics Developer of biological tissue imaging by using optical coherence tomography | $63M | 49 mo ago | Series E | 29 | — | — | 253 patents Intravascular optical imaging and laser ablation guidance using fiber‑based catheters | — |
| 4 | STAT Diagnostica Provider of a diagnostic platform for molecular diagnostics and immunoassays | $54M | 116 mo ago | Series C | — | Jordi Carrera Co-Founder & Managing Director | — | 113 patents Microfluidic cartridges for nucleic acid purification and on‑chip biochemical assay processing | — |
| 5 | Ona Therapeutics Provider of therapeutics solution for metastatic cancer | $35M | 8 mo ago | Series A | 25 | Valerie Vanhooren Co-Founder & CEO | WordPressBugHerdMySQL+19 | 30 patents FGFR4 and CD36 targeted therapeutics for cancer treatment | — |
| 6 | SOM Biotech Developer of platform for screening compounds to treat rare diseases | $29M | 30 mo ago | Series B | 15 | Raul Insa Founder & CEO | — | 117 patents Pharmaceutical compounds and formulations for treating dystrophinopathies, movement disorders, and PKU | — |
| 7 | Highlight Therapeutics Developer of RNA-based therapies for dermato-oncology conditions and skin cancers | $27M | 9 mo ago | Series B | 23 | — | WordPressMySQLPHP+15 | 37 patents Formulating double-stranded RNA (poly‑I:C) complexes for immunomodulatory therapeutics. | — |
| 8 | Oncomatryx Developer of antibody-drug conjugates targeting the tumor microenvironment | $26M | 2 mo ago | Series D | 19 | — | WordPressMySQLPHP+14 | — | — |
| 9 | ORYZON Developer of treatments solutions for cancer and neurodegenerative diseases using epigenetic technology… | $25M | 14 mo ago | Public | 43 | Carlos Buesa CEO | DrupalApple iCloud MailMicrosoft 365+10 | — | — |
| 10 | Peptomyc Cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment | $23M | 2 mo ago | Series C | 18 | Marie-Eve Beaulieu Co-Founder | WordPressMySQLPHP+16 | 60 patents Patents concentrated in health & consumer products | — |
| 11 | AbilityPharma Developer of drugs for the treatment of cancer diseases | $15M | 27 mo ago | Series B | 19 | Jordi Espadaler Co-Founder | Google MapsApache HTTP Serverlit-html+7 | — | — |
| 12 | Nuage Therapeutics Developer of drugs designed for intrinsically disordered targets | $13M | 36 mo ago | Seed | 15 | Judit Folgueira Co-Founder & CEO | WordPressMySQLPHP+21 | — | — |
| 13 | Laminar Pharma Developer of melipathy based drugs | $12M | 23 mo ago | Series A | 30 | — | WordPressPleskMySQL+29 | — | — |
| 14 | Mimark Developer of diagnostic solutions for treating patients with gynecological problems | $7M | 31 mo ago | Seed | 2 | Antonio Moreno Co-Founder & CMO | WordPressMySQLPHP+15 | — | — |
| 15 | Onechain Immunotherapeutics Developer of immunotherapies against hematological malignancies | $7M | 27 mo ago | Seed | 10 | Pablo Menendez Founder | RubyTrixYouTube+7 | 28 patents Targeted antibody-based immunotherapies and engineered Vδ1 T-cell therapies for cancer | 1 internship |
| 16 | Amadix Provider of diagnostic tools to support personalized cancer treatment | $7M | 16 mo ago | Series A | 35 | Rocio Arroyo CEO | WordPress Block EditorElementorWordPress+25 | — | — |
| 17 | Iteria Biopharma Developer of medicinal chemistry treatments for difficult to modulate targets | $6M | 2 mo ago | Seed | — | Julio Castro Co-Founder | WordPressMySQLPHP+24 | — | — |
| 18 | Formune Developer of therapeutic vaccines for infectious cancer | $6M | 165 mo ago | Deadpooled | — | Carles Domenech CEO | — | — | — |
| 19 | Protein Alternatives Developer of diagnostic assays and therapeutics for the treatment of cancer | $5M | 86 mo ago | Funding Raised | — | Martín Pou Romay CEO & MD | — | — | — |
| 20 | Inbiomotion Developer of biomarkers to predict bone metastasis in cancer patients | $5M | 65 mo ago | Series A | 10 | — | — | 80 patents Personalized cancer diagnostics and therapies targeting c-MAF biomarkers in breast and prostate tumors | 1 partnership |
| 21 | Gyala Therapeutics Developer of cell therapies for the treatment of hematological malignancies | $4M | 4 mo ago | Early Stage | 5 | — | — | 9 patents CD84-targeted antibodies and CAR‑T cell immunotherapies for cancer treatment | — |
| 22 | Onena Medicines. Developer of immunotherapies for the treatment of breast cancer | $4M | 31 mo ago | Series A | 10 | Maider Zabala Co-Founder | — | 5 patents Therapeutic antibodies targeting LEFTY signaling proteins | — |
| 23 | Leukos Biotech Developer of drugs targeting leukemic stem cells | $4M | 62 mo ago | Series A | 4 | — | — | 55 patents Selective 5-HT1B receptor modulators for solid tumor treatment | — |
| 24 | Oncostellae Developer of small molecule drugs for cancer, inflammatory and auto-immune disorders | $4M | 35 mo ago | Series A | 13 | — | — | 55 patents Small-molecule kinase inhibitors and steroid receptor modulators for oncology and endocrine therapy | — |
| 25 | Adaptam Therapeutics Developer of antibody-based immunotherapies targeting the immunosuppressive myeloid tumor microenvironment | $3M | 7 mo ago | Seed | — | Asis Palazon Founder & CEO/CSO | — | 4 patents Therapeutic antibodies targeting Siglec‑9 and Siglec‑15 immune‑checkpoint proteins | — |
| 26 | Medibiofarma Developer of drugs for treating cancer | $3M | 26 mo ago | Seed | 8 | Rodolfo Rodriguez Iglesias Founder | — | 60 patents Small-molecule modulators of PGE2 receptors, PPAR‑γ agonists, and HDAC1/2 inhibitors | — |
| 27 | AptaTargets Provider of therapeutic solutions for ischemic diseases | $3M | 94 mo ago | Series A | 10 | Victor Manuel Gonzalez Muñoz Cofounder and Scientific Advisor | — | — | — |
| 28 | Gate2Brain Developer of platform for the delivery of therapeutics across biological barriers | $3M | 34 mo ago | Funding Raised | 10 | Esther Riambau Co-Founder | — | 14 patents Peptide-based water‑soluble delivery platforms for anticancer drugs and BBB‑crossing antibody therapeutics | 1 partnership |
| 29 | Aptadel Therapeutics Developer of RNA-based therapeutics to treat cancer | $3M | 3 mo ago | Seed | 7 | Oscar Tirado Co-Founder | — | 3 patents Aptamer therapeutics targeting EPHA2 receptor for cancer treatment | 1 launch |
| 30 | Origo Biopharma Manufacturer of immunotherapeutic products for research purpose | $3M | 71 mo ago | Acqui-Hired | 10 | Ramon Bosser CEO | — | 13 patents Small-molecule inhibitors of TGF‑β receptor I (ALK5) kinase for therapeutic modulation | — |
| 31 | Lykera biomed Monoclonal antibodies (MAbs) as therapy for solid tumors | $2M | 120 mo ago | Deadpooled | 1 | Juan Ruiz CEO | — | 55 patents Antibody therapeutics targeting S100 family proteins for cancer and fibrotic disease treatment and diagnostics | — |
| 32 | Transbiomed Provider of genomics and proteomics based molecular diagnostics solutions | $2M | 184 mo ago | Deadpooled | — | Andreas Doll Co-Founder | — | — | — |
| 33 | Arjuna Therapeutics Developer of small molecule therapeutics to treat cancer | $2M | 42 mo ago | Seed | 8 | Darren Bianchi Co-Founder & Board Member | — | — | — |
| 34 | Oniria Therapeutics Developer of therapeutics for cancer treatment | $1M | 37 mo ago | Seed | 7 | Josep Tabernero Co-Founder | — | — | 2 partnerships |
| 35 | Nanobots Therapeutics Developer of therapeutics for the treatment of cancer | $509K | 18 mo ago | Seed | 6 | Andres Fernandez Co-Founder | Froala EditorVimeoBootstrap+14 | — | 1 award |
| 36 | Pangaea Biotech Provider of drug development and molecular diagnostics services on cancer treatment | $298K | 101 mo ago | Public | 55 | — | WordPressMySQLPHP+22 | 104 patents Molecular diagnostics and targeted oncology therapeutics using nucleic acid isolation and luminescent assays | 1 award |
| 37 | YSOTOPE Developer of radiotracers to monitor CAR-T cells inside the patient’s body | $160K | 35 mo ago | Seed | 5 | Carlos Gavilan Co-Founder & CEO | — | — | — |
| 38 | Xenopat Developing xenograft models of cancer for drug development and personalized treatment selection | $158K | 65 mo ago | Funding Raised | 4 | Alberto Villanueva Co-Founder | — | — | — |
| 39 | EntreChem Developer of natural origin small molecule drugs for cancer | $150K | 137 mo ago | Funding Raised | — | Francisco Moris Co-Founder & Managing Director | — | — | — |
| 40 | Imegen Provider of genetic tests for the detection of various disease conditions | $140K | 108 mo ago | Acquired | 65 | Manuel Alonso Founder | — | — | — |
| 41 | MiWEndo Solutions Developer of electromagnetic endoscopy for colorectal cancer detection | $121K | 64 mo ago | Seed | 19 | Gloria Esparrach Co-Founder | WordPressMySQLPHP+22 | 2 patents Medical endoscopic accessories for gastrointestinal procedures | — |
| 42 | Moirai Biodesign Developer of RNA-based therapeutics and diagnostics for cancer | $115K | 84 mo ago | Seed | 6 | Ivan Dotu Co-founder and CTO | — | — | — |
| 43 | Canvax Biotech Spanish biotech company with 3 businesses - drug discovery, biosensors and R&D tools | $111K | 127 mo ago | Funding Raised | — | Jose Huertas Jimenez Co-Founder | WordPressMySQLPHP+22 | 34 patents Patents concentrated in health & consumer products | 1 launch |
Top 12 Oncology companies in Spain
#1
Series C · Seville, Andalusia · founded 2012 · 61 employees$126.1Mraised▾
Developer of non-invasive blood-based diagnostics for cancer. The company is developing a screening test that uses metabolomics to analyze patient blood samples and detect early signs of disease. It has developed tests for the early detection of colorectal cancer, lung cancer, and breast cancer.
- Jan 2026Series C$35M
- Feb 2025Venture Debt$21M
- Aug 2024Series B—
- Nov 2023Series B$70M
#2
Series C · Barcelona, Catalonia · founded 2014 · 18 employees$22.6Mraised▾
Peptomyc, a spin-off of the Vall d’Hebron Institute of Oncology (VHIO) is focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. Its lead peptide Omomyc-CPP is in the preclinical stage.
- Apr 2026Series C$5.8M
- Feb 2026Series B—
- Oct 2023Grant (prize money)$2.6M
- Oct 2023Series B$2.6M
#3
Series D · Derio, Basque Country · founded 2009 · 19 employees$26.2Mraised▾
Developer of antibody-drug conjugates targeting the tumor microenvironment. It develops novel therapies focused on modulating the tumor's microenvironment to overcome resistance to conventional cancer treatments. The company conducts clinical trials and is committed to bringing innovative solutions to cancer patients. Research efforts concentrate on understanding and targeting the tumor stroma, a new avenue for treating metastatic solid tumors. This approach involves orchestrated combinations of precision drugs targeting both the tumor and its surrounding microenvironment.
- Mar 2026Series D$67M
- Jan 2025Series C$26.2M
- Apr 2022Series B$16.2M
- Nov 2019Series A$10M
#4
Series A · Barcelona, Catalonia · founded 2019 · 25 employees$35.5Mraised▾
Ona Therapeutics provides therapeutics solution for metastatic cancer. It is a spin-off of ICREA and IRB and involved in developing biologics targeting the metastatic-initiating cells and lipid metabolism for the treatment of cancer.
- Oct 2025Series A$11.6M
- Dec 2020Grant (prize money)—
- Jun 2020Series A$33.8M
- May 2019Seed$1.7M
#5
Seed · Spain · founded 2024$5.9Mraised▾
Developer of medicinal chemistry treatments for difficult to modulate targets. This entity focuses on the application of chemical methods to address medical needs in oncology. Research efforts target pharmacologically validated proteins that are resistant to standard drug discovery techniques. Development activities include the creation of candidates protected by intellectual property rights and the management of projects through early development stages.
- Apr 2026Seed$5.9M
#6
Series B · Paterna, Valencian Community · founded 2010 · 23 employees$27.1Mraised▾
Developer of RNA-based therapies for dermato-oncology conditions and skin cancers. Its lead drug candidate triggers immune responses, transforming tumors, making them visible. The company focuses on research and therapies offering hope for healthier skin. It aims to address the challenges behind common cancers.
- Sep 2025Series B$17.6M
- Feb 2021Series B$27.1M
- Jan 2015Grant (prize money)$299.6K
#7
Seed · Barcelona, Catalonia · founded 2020 · 7 employees$2.8Mraised▾
Developer of RNA-based therapeutics to treat cancer. The company's technology is based on RNA-Aptamers to deliver different therapeutic agents to treat a wide variety of cancers. The company's lead candidate drug is ADEL-101 for Ewing Sarcoma, a rare variety of bone cancer in children and young adults.
- Mar 2026Seed$2.3M
- 2025Seed$498.5K
#8
Early Stage · Barcelona, Catalonia · founded 2020 · 5 employees$4.4Mraised▾
Developer of cell therapies for the treatment of hematological malignancies. The company is developing CAR T cell products against a novel target overexpressed in several hematological malignancies. The product line inlcudes ARI-0001 and ARI-0002 for chronic lymphocytic leukemia (CLL), Burkitt’s lymphoma, acute myeloid leukemia (AML), or T-cell acute lymphoblastic leukemia (T-ALL).
- Feb 2026Grant (prize money)$4.4M
#9
Public · Barcelona, Catalonia · founded 2000 · 43 employees$24.9Mraised▾
Developer of treatments solutions for cancer and neurodegenerative diseases using epigenetic technology platforms. It uses a proprietary epigenetic platform to identify drug targets for cancer and neurodegenerative diseases. Its lead candidate targets lysine-specific demethylase - 1 (LSD-1) for Alzheimer's, Parkinson's, Huntington's, and certain other rare diseases.
- Apr 2025Post IPO$34.1M
- Sep 2021Grant (prize money)$1M
- Jul 2019Post IPO$22.3M
- Mar 2017Post IPO$19.5M
#10
Seed · San Sebastian, Basque Country · founded 2023$3.5Mraised▾
Developer of antibody-based immunotherapies targeting the immunosuppressive myeloid tumor microenvironment. It focuses on creating therapies directed to novel targets expressed in immunosuppressive myeloid cells. These therapies include antibody-drug conjugates and bispecific antibodies for oncology indications. The organization advances first-in-class antibody-based therapies.
- Oct 2025Seed$3.5M
#11
Series A · Madrid, Community of Madrid · founded 2010 · 35 employees$6.9Mraised▾
Provider of diagnostic tools to support personalized cancer treatment. The company has developed prognostic, diagnostic, and predictive tests for lung cancer, colorectal cancer, and prostate cancer. Its colon cancer test ColoFast is a blood-based miRNA test for early detection of colon cancer. It is also developing DiagnoLung which is a blood-based ELISA test that measures the level of three protein biomarkers to screen high-risk patients for non-small-cell lung cancer.
- Feb 2025Venture Debt$15.6M
- Aug 2022Grant (prize money)$2.6M
- Jun 2021Grant (prize money)$3.4M
- Oct 2020Grant (prize money)$152.1K
#12
Series A · Palma, Balearic Islands · founded 2006 · 30 employees$12Mraised▾
Developer of melipathy based drugs. The company provides various products such as LAM561 anticancer drug acting through cell membrane modification, LAM226 Omega-3 lipid derivative which specifically targets neuronal membranes for Alzheimer’s, LAM204 polyunsaturated fatty acid to replace steroid anti-inflammatory treatments and LAM30171 fatty acid derivative as a potential treatment for cancer and metabolic disorders.
- Jul 2024Series A$6.3M
- Oct 2023Series A$8.4M
- Nov 2022Grant (prize money)$280.5K
- Apr 2021Grant (prize money)$189.4K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Spain
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 933 Spain-affiliated papers.
- Centro de Investigación Biomédica en Red de Cáncer107
- Clinica Universidad de Navarra82
- Cancer Research Center60
- Instituto de Salud Carlos III55
- Universidad de Navarra49
- Tumor microenvironment4→118
- Immune system2→83
- Cancer research5→70
- Immunotherapy3→66
- Cancer immunotherapy3→31
- Tumor microenvironment7→193
- Immune system4→148
- Immunotherapy6→136
- Cancer research12→131
- Cancer immunotherapy6→62
- Tumor microenvironment5→57
- Immunotherapy6→58
- Immune system6→45
- Cancer immunotherapy3→28
- Cancer research3→18
Where oncology is researched across Spain
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.